{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055781","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.437270+00:00","generated_at":"2026-06-15T22:35:39.404978+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicycle Therapeutics Q1 net loss $39.1M; cash $293.8M; Novartis deal advances BRC pipeline","bullets":["Net loss of $39.1M ($1.30 per share) vs $27.6M ($0.93 per share) in Q1 2022.","R&D expenses rose to $32.2M from $14.3M, driven by BT8009, BT5528, and TICA programs.","Cash $293.8M at March 31, 2023 (excluding $50M Novartis upfront); runway into 2025.","Entered Novartis collaboration for Bicycle radio-conjugates; eligible for up to $1.7B milestones.","BT8009 Phase I dose escalation showed median duration of response ~14 months in urothelial cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055781","json":"https://secwatch.observer/filing/0001104659-23-055781.json","markdown":"https://secwatch.observer/filing/0001104659-23-055781.md","text":"https://secwatch.observer/filing/0001104659-23-055781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923055781/0001104659-23-055781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923055781/tm2314590d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:35:39.404978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf91e85ed6eb2164766c52c5dec764feea49a76f","claim":"BICYCLE THERAPEUTICS PLC reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761612/000110465923055781/0001104659-23-055781-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}